Hoke Austin T K, Malfitano Madison, Zanation Adam M, Ebert Charles S, Senior Brent A, Kimple Adam J, Thorp Brian D
Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel, North Carolina, United States.
J Neurol Surg B Skull Base. 2021 Dec 17;83(4):397-404. doi: 10.1055/a-1692-9879. eCollection 2022 Aug.
Pain management remains a point of emphasis given the ongoing opioid crisis. There are no studies in the literature interrogating opioid prescribing and use following endoscopic pituitary surgery. This study investigates provider prescribing tendency, patient utilization of analgesics, and patient outcomes regarding pain management after endoscopic pituitary surgery. We identified 100 patients undergoing endoscopic pituitary surgery at one institution from 2016 to 2018 in the electronic medical record (EMR) and state narcotic database to determine postoperative analgesic regimens. A telephone survey was used to characterize postoperative analgesic use and satisfaction with prescribed regimen. Fifty-two different pain control regimens were prescribed to the study patients. Also, 93% of study patients were prescribed an opioid postoperatively. The average quantity of opioids prescribed per patient in morphine milligram equivalents (MMEs) was 625 (equivalent 83 oxycodone 5-mg tablets) with an average MME/day of 59 (equivalent 8 oxycodone 5-mg tablets). A total of 71% survey respondents who used opioids reported using <25% of their prescription. The majority of prescription narcotic users consumed >50% of their postoperative opioid intake in the first 24 to 48 hours after discharge. There were no significant differences in pain outcome between opioid users and nonopioid users. Vast heterogeneity exists in narcotic prescribing by providers at our institution following endoscopic pituitary surgery. Narcotic prescribing patterns exceeded most patients' analgesic needs. Opioid analgesics were not superior to nonopioids regimens in patient-reported pain outcomes in this study population.
鉴于持续的阿片类药物危机,疼痛管理仍然是一个重点。文献中没有关于内镜垂体手术后阿片类药物处方和使用情况的研究。本研究调查了内镜垂体手术后医生的处方倾向、患者对镇痛药的使用情况以及疼痛管理方面的患者预后。
我们在电子病历(EMR)和州麻醉品数据库中识别了2016年至2018年在一家机构接受内镜垂体手术的100名患者,以确定术后镇痛方案。通过电话调查来描述术后镇痛药的使用情况以及对规定方案的满意度。
研究患者共被开出了52种不同的疼痛控制方案。此外,93%的研究患者术后被开了阿片类药物。每位患者以吗啡毫克当量(MME)计的阿片类药物平均处方量为625(相当于83片5毫克羟考酮片剂),平均每日MME为59(相当于8片5毫克羟考酮片剂)。在使用阿片类药物的调查受访者中,共有71%报告使用的药物不到其处方量的25%。大多数处方麻醉药品使用者在出院后的头24至48小时内消耗了其术后阿片类药物摄入量的50%以上。阿片类药物使用者和非阿片类药物使用者在疼痛预后方面没有显著差异。
在我们机构,内镜垂体手术后医生的麻醉药品处方存在很大的异质性。麻醉药品处方模式超出了大多数患者的镇痛需求。在该研究人群中,患者报告的疼痛结果方面,阿片类镇痛药并不优于非阿片类药物方案。